Essex Financial Services, Inc. Novo Cure LTD Transaction History

Essex Financial Services, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$56.6 - $89.9 $192,836 - $306,289	-3,407 Closed	0 $0
Q1 2022 Apr 21, 2022	BUY	$60.15 - $84.52 $6,436 - $9,043	107 Added 3.24%	3,407 $282,000
Q3 2021 Nov 10, 2021	BUY	$116.17 - $194.55 $37,755 - $63,228	325 Added 10.92%	3,300 $383,000
Q1 2021 May 11, 2021	SELL	$124.11 - $190.17 $77,568 - $118,856	-625 Reduced 17.36%	2,975 $393,000
Q4 2020 Feb 05, 2021	BUY	$112.16 - $174.14 $19,628 - $30,474	175 Added 5.11%	3,600 $623,000
Q3 2020 Nov 10, 2020	SELL	$58.05 - $111.31 $30,476 - $58,437	-525 Reduced 13.29%	3,425 $381,000
Q2 2020 Aug 06, 2020	SELL	$57.2 - $74.41 $137,280 - $178,584	-2,400 Reduced 37.8%	3,950 $234,000
Q4 2019 Jan 30, 2020	BUY	$68.3 - $93.8 $433,705 - $595,630	6,350 New	6,350 $535,000

263

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $3.25B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Essex Financial Services, Inc., based on Form 13F filings with the SEC.

Stay updated on Essex Financial Services, Inc. with notifications on news.